Clark William D's Form 4 filing
Genocea Biosciences, Inc. (GNCA) · filed Jun 2, 2022
- Accession no.
- 0001457612-22-000069
- Filed
- Jun 2, 2022, 4:31 PM ET
- Trade date
- May 31, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $7.23K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Clark William DCIK 0001355415 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 31, 2022 | Common Stock | SSaleDisposed | −117,244 | $0.0617F1 | −$7,233.95 | 308,400 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
1. Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.061 to $0.0628, inclusive.
Referenced by the price of 1 transaction in Table I.